Work

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-158465

Authors: Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A. Podoltsev, Maximilian F. Stahl, Jessica M. Stempel, Eytan Stein, Scott F. Huntington, Amer M. Zeidan

Institutions: Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, Harvard University, Yale University, Yale Cancer Center, Dana-Farber Cancer Institute

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310114344

FWCI: 0.196

Cites:

Cited by: 1

Related to: 10